November 27, 2018
Alcon spinoffs from Novartis in first half of 2019
Novartis’s eye care division Alcon, on Tuesday has its first Capital Markets Day for investors and analysts as a tax-neutral,…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
November 27, 2018
ADC Therapeutics dosed first patients clinically testing its drug in relapsed or refractory B-cell Acute Lymphoblastic Leukemia
ADC Therapeutics has dosed the first patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), in a Phase I/II…
November 27, 2018
Germany company Adrenomed raises €24 million to push Adrecizumab’s clinical trial
German privately financed vascular integrity company Adrenomed has closed a €24 million series D financing round co-led by Wellington Partners…
November 27, 2018
Julca Combination approved in Japan for treating HIV
ViiV Healthcare and Janssen Sciences Ireland UC’s Juluca Combination Tablets for treating HIV (type 1) was approved by the Ministry…
November 27, 2018
Sandoz gets marketing pass in EU for Ziextenzo, for helping treat cancer with cytotoxic chemotherapy in adults
Novartis’ Sandoz, received on Tuesday from the European Commission (EC) the marketing authorization for biosimilar Ziextenzo (pegfilgrastim), which is indicated to reduce the…
November 23, 2018
EU approves Novartis’ the one-time gene therapy Luxturna
Novartis’ Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation, developed…
November 23, 2018
Curetis nears clearing BAL as additional sample type for Unyvero LRT
The U.S. FDA confirmed that data required for the submission can largely be based on clinical samples previously collected during…
November 22, 2018
Oasmia’s Apalea approved in Europe for ovarian cancer
After the Oasmia Pharmaceutical’s pivotal study OAS 07OVA conducted on ovarian cancer patients with disease relapse, showed that the risks…
November 22, 2018
GSK, Kyowa Hakko Kirin mutual work on potential oral treatment for CKD related anaemia
GSK and Kyowa Hakko Kirin will together commercialize in Japan the treatment of chronic kidney disease related anaemina, which GKS…
November 21, 2018
Sandoz, Pear Therapeutics launch reSET for patients with Substance Use Disorder
Novartis’s division Sandoz, and Pear Therapeutics, have launched reSET for patients with Substance Use Disorder (SUD), which is th efirst…